{"Clinical Trial ID": "NCT00203502", "Intervention": ["INTERVENTION 1:", "Intervention: Drug: Docetaxel + Cyclophosphamide + Avastin", "Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2", "+ Avastin 15 mg/kg", "Q 3 weeks X 4 cycles", "Bevacizumab/Avastin: IV 15mg/kg 21 days", "Cyclophosphamide: 500mg per square metre, IV every 21 days", "Doxorubicin: 60 mg per square metre, IV every 21 days"], "Eligibility": ["Incorporation criteria:", "The diagnosis of breast cancer established by biopsy.", "Normal renal function", "\u2022 Normal LVEF evaluated by MUGA Scan", "> 18 years", "Good performance defined by the ECOG scale of 0 or 1", "Consent", "Women of childbearing potential must undergo a negative pregnancy test.", "Use of effective contraceptives in subjects of childbearing potential during treatment and for at least 3 months thereafter.", "Peripheral neuropathy: must be < grade 1", "Haematological (minimum values)", "Absolute neutrophil count > 1,500/mm3", "Hemoglobin > 8.0 g/dl", "Number of platelets > 100 000/mm3", "Hepatic", "Total bilirubin <ULN", "AST, ALT and Alkaline Phosphatase must be within range", "- Exclusion criteria:", "Patients with locally advanced breast cancer with skin ulceration", "Stage IV breast cancer", "Inflammatory breast cancer", "Allergy to any component of the treatment", "Breastfeeding women", "Pregnancy or refusal to use effective contraception", "The inability to comply with study and/or follow-up procedures.", "Current, recent or planned participation in an experimental drug study", "Blood pressure > 150/100 mmHg. Well controlled essential hypertension with antihypertensive agents is not an exclusion criterion.", "- Unstable angina", "New York Heart Association Grade II or greater congestive heart failure", "History of myocardial infarction within 6 months", "History of stroke within 6 months", "Clinically significant peripheral vascular disorders", "Evidence of haemorrhagic diathesis or coagulopathy", "Presence of central nervous system or brain metastases", "\u2022 Major surgery, open biopsy or significant traumatizing injury within 28 days prior to day 0", "\u2022 Minor surgery such as fine needle aspirations or heart biopsy within 7 days prior to day 0", "\u2014 Pregnant or lactating", "Urine: creatinine ratio > 1.0 at screening", "History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to day 0", "A serious, non-healing injury, ulcer or bone fracture"], "Results": ["Performance measures:", "Percentage of participants with a complete pathological response.", "The complete pathological response was defined as the absence of invasive and in situ residual cancer on hematoxyline and eosin in the resected breast assessment.", "Duration: Participants were evaluated during surgery, on average one hour", "Results 1:", "Title of the arm/group: Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin", "Description of the arm/group: Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2", "+ Avastin 15 mg/kg", "Q 3 weeks X 4 cycles", "Bevacizumab/Avastin: IV 15mg/kg 21 days", "Cyclophosphamide: 500mg per square metre, IV every 21 days", "Doxorubicin: 60 mg per square metre, IV every 21 days", "Total number of participants analysed: 39", "Type of measurement: Number", "Unit of measure: percentage of patients evaluated 41 (27.7 to 55.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 39/39 (100.00 per cent)", "Febrile Neutropenia 1/39 (2.56%)", "1/39 (2.56%)", "Diarrhoea 3/39 (7.69%)", "Nausea/vomiting 4/39 (10.26 per cent)", "Mucositis 3/39 (7.69 per cent)", "Fatigue 4/39 (10.26 per cent)", "Infection 3/39 (7.69%)", "urinary infection 2/39 (5.13%)", "Musculoskeletal pain 6/39 (15.38%)", "Syncope 1/39 (2.56%)", "Insomnia 3/39 (7.69%)", "Anxiety 2/39 (5.13 per cent)"]}